Abbott Buys CSI To Add Peripheral And Coronary Atherectomy Technologies
CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.
You may also be interested in...
News We're Watching: Amazon Drops Wearables, FDA Warns Of Cyber Threat, Researchers Find Parkinson's Biomarker
This week, the FDA issued a cybersecurity threat to gene sequencing platforms from Illumina and Amazon announced it was getting out of the fitness wearables business, while researchers announced a breakthrough in Parkinson's diagnostics.
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.